Back to Journals » OncoTargets and Therapy » Volume 10

Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis

Authors Hao Y, Fu Q, Guo Y, Ye M, Zhao H, Wang Q, Peng X, Li Q, Wang R, Xiao W

Received 5 October 2016

Accepted for publication 17 December 2016

Published 16 February 2017 Volume 2017:10 Pages 945—953

DOI https://doi.org/10.2147/OTT.S123954

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Dr XuYu Yang

Yi-Xin Hao,1,* Qiang Fu,2,* Yan-Yan Guo,1 Ming Ye,1 Hui-Xia Zhao,1 Qi Wang,1 Xiu-Mei Peng,1 Qiu-Wen Li,1 Ru-Liang Wang,1 Wen-Hua Xiao1

1Department of Oncology, First Affiliated Hospital, 2Department of Anesthesiology, People’s Liberation Army General Hospital, Beijing, People’s Republic of China

*These authors contributed equally to this work

Abstract: Circulating tumor DNA (ctDNA) can be identified in the peripheral blood of patients and harbors the genomic alterations found in tumor tissues, which provides a noninvasive approach for detection of gene mutations. We conducted this meta-analysis to investigate whether ctDNA can be used for monitoring KRAS gene mutations in colorectal cancer (CRC) patients. Medline, Embase, Cochrane Library and Web of Science were searched for the included eligible studies in English, and data were extracted for statistical analysis according to the numbers of true-positive (TP), true-negative (TN), false-positive (FP) and false-negative (FN) cases. Sensitivity, specificity and diagnostic odds ratio (DOR) were calculated, and the area under the receiver operating characteristic curve (AUROC) was used to evaluate the diagnostic performance. After independent searching and reviewing, 21 studies involving 1,812 cancer patients were analyzed. The overall sensitivity, specificity and DOR were 0.67 (95% confidence interval [CI] =0.55–0.78), 0.96 (95% CI =0.93–0.98) and 53.95 (95% CI =26.24–110.92), respectively. The AUROC was 0.95 (95% CI =0.92–0.96), which indicated the high diagnostic accuracy of ctDNA. After stratified analysis, we found the higher diagnostic accuracy in subgroup of patients detected in blood sample of plasma. The ctDNA may be an ideal source for detection of KRAS gene mutations in CRC patients with high specificity and diagnostic value.

Keywords: cancer, KRAS, mutation, circulating tumor DNA

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]